Professional Documents
Culture Documents
Insulin resistance is the cornerstone of multiple diseases such as metabolic syndrome, diabetes
mellitus, arterial hypertension, dyslipidemia, acute coronary syndrome, etc.
There are some medications and changes in lifestyle that can reduce insulin resistance. Not all
are suitable for all patients.
We discovered another pharmacologic agent that can be successfully added to the old methods
already in use.
Key words: insulin resistance, Gerovital H3, metabolic syndrome.
Insulin resistance (IR) is one of the cornerstones of several syndromes with large impact on
arterial diseases: metabolic syndrome, diabetes
mellitus, hypertension, acute coronary syndrome,
etc. [1,4].
There are a lot of known methods that reduce
IR, but their efficiency is not always long-lasting
and not so powerful for every product [3]. That is
why in the treatment of IR we combine different
methods adapted to every patients needs, in order
to obtain the maximum benefit for the individual
therapy [3,4]. The methods of reducing IR include
weight loss, physical activity, medication (metformin,
pioglitazone), correction of hyperglycemia, hypernatremia, hyperlipidemia, etc. [2,5].
As we already mentioned, depending on the
present factors that increase IR, we adapt the therapy
to every patients needs. Unfortunately, there are a
lot of other not yet identified factors that make IR
present and capable of inducing dysfunction or
atherosclerosis of the arterial vessels [11].
As a result of an extensive experience in the
field of IR, we observed that this phenomenon can
also be reduced by other methods. One of them was
far more efficient compared with the others. It is a
product with an international name (Gerovital H3)
usually used in geriatric medicine. We observed
that this pharmacologic agent improves insulin sensitivity, not only in the insulin-treated patients. We
administered 10 mL of this substance by i.m. injection
every day, for the period taken in observation.
ROM. J. INTERN. MED., 2014, 52, 4, 233238
234
T. Mogo et al.
235
236
T. Mogo et al.
Figure 5. Decrease in IR in the female group after 2w and 3w of treatment with Gerovital H3.
Figure 6. Decrease in IR in the male group after 2w and 3w of treatment with Gerovital H3.
Figure 7. Decrease of the total daily insulin requirements after treatment with Gerovital H3.
237
Figure 8. Decrease of the glycaemic levels after treatment with Gerovital H3.
DISCUSSION
CONCLUSION
238
T. Mogo et al.